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Abstract
Purpose Identification of vulnerable plaques remains crucial
for better cardiovascular risk assessment. At least 20% of
inflammatory cells within unstable (vulnerable) plaques com-
priseTlymphocytes,whichcontainreceptorsforinterleukin-2
(IL-2); those receptors can be identified by scintigraphy with
radiolabelled IL-2.The aim of this study was to identify the
“inflamed” (vulnerable) plaques by scintigraphy using IL-2
labelled with
99mTc in the selected, high cardiovascular risk
group of end-stage renal disease (ESRD) patients.
Methods A total of 28 patients (18 men, 10 women, aged
55.2±9.6 years, 17 on peritoneal dialysis, 11 on haemodial-
ysis) underwent common carotid artery (CCA) scintigraphy
with the use of
99mTc-hydrazinonicotinamide (HYNIC)-IL-2.
In all cases, ultrasound examination of the CCA was per-
formed and levels of selected proinflammatory factors, ath-
erogenic markers and calcium-phosphate balance parameters
weremeasured. Finally, the target tonon-target (T/nT) ratio of
IL-2 uptake in atherosclerotic plaques with intima-media
thickness (IMT), classic cardiovascular risk factors and con-
centrations of the measured factors were compared.
Results Increased
99mTc-HYNIC-IL-2 uptake in atherosclerot-
icplaquesin38/41(91%)caseswasdetected.ThemedianT/nT
ratio of focal
99mTc-HYNIC-IL-2 uptake in atherosclerotic
plaques was 2.35 (range 1.23–3.63). The mean IMT value on
the side of plaques assessed by scintigraphy was 0.79±
0.18 mm (median 0.8, range 0.5–1.275).
Correlations between T/nT ratio and homocysteine
(R00.22, p00.037), apolipoprotein B (apoB) (R00.31,
p00.008), apoB to apoA-I ratio (R00.29, p00.012) and
triglyceride concentration (R00.26, p00.021) were
detected. A lower T/nT ratio in patients with better
parameters of nutritional status (haemoglobin, albumin, adi-
ponectin) in comparison with patients with worse nutritional
parameters (3.20±0.5 vs 2.16±0.68, p00.025) was revealed as
well as a difference between values of T/nT ratio in groups of
patients with values of apoB, soluble CD40 ligand and
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Conclusion Scintigraphy with the use of
99mTc-HYNIC-IL-2
can be a tool for inflamed atherosclerotic (vulnerable) plaque
visualization within CCA in ESRD patients. Quantitative
results of carotid artery scintigraphy with
99mTc-HYNIC-IL-2
correlate with serum concentration of selected cardiovascular
risk markers.
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Introduction
Routinely used methods for quantification of short-term car-
diovascular risk are considered inefficient. Most of the avail-
able methods are based on insight into the arterial lumen,
namely assessment of atherosclerotic plaque size, its degree
of calcification or intima-media complex thickness measure-
ments. These methods may, however, be imprecise in identi-
fying “vulnerable patients” with plaques at the highest risk of
rupture. Providing such information would seem to be very
important since it may potentially result not only in more
sensitiveselection ofpatientsforinvasiveprocedures,butalso
for choosing candidates best suited to aggressive conservative
treatment (leading to stabilization of “vulnerable” plaques).
This kind of information may potentially be obtained with
scintigraphyusingdeliberatelychosentracers.Amongavariety
of candidates, the most promising substances are those in-
volved in regulation of the inflammatory process.
Interleukin-2 (IL-2) was identified in 1975 as a growth
factor for T lymphocytes and is now considered one of the
most important modulators of the inflammatory response.
IL-2 is produced mainly by the CD4+ lymphocyte subpop-
ulation, and its biological activity is attained after binding to
specific receptors located, among other target cells, on these
lymphocytes [1]. IL-2 induces autoproliferation of helper T
cells and cytotoxic lymphocytes as well as B lymphocytes,
NK (natural killer) and memory cells [2]. IL-2 secretion by
activated lymphocytes also stimulates other immunomodu-
lating cytokines, such as interferon gamma (IFN-γ) or tu-
mour necrosis factor beta (TNF-β), which in turn interact
with cells from the monocyte/macrophage lineage, endothe-
lial layer and fibroblasts leading to fibrous cap thickening
and plaque vulnerability.
IL-2 radiolabelled with
99mTc or
123I has previously been
proven a useful tracer in imaging of the lymphocytic tissue
infiltration in patients with autoimmune disorders [3–5]o r
lymphocyteinfiltration intoatherosclerotic plaques inpatients
with symptomatic atherosclerosis [6, 7].
In certain populations, including patients with end-stage
renaldisease(ESRD),cardiovasculardiseaseismorecommon
and more accelerated than in the general population. This
makes the ESRD group a valuable “model” for advanced
and rapidly progressing atherosclerosis, useful for clinical
studies. The increased cardiovascular mortality in ESRD
patients is based mainly on a chronic inflammatory process
(the malnutrition-inflammation-atherosclerosis syndrome) as
well as chronic anaemia, bone and mineral disorders, hyper-
tension and uraemia with derangement of the biochemical
milieu with accumulation of several cardiotoxic and athero-
genic substances. Most of these abnormalities mentioned are
poorly corrected with dialysis [8].
Serum concentrations of a wide range of inflammatory
agents that promote atherosclerosis or indicate severity of
endothelialimpairmentareusedtoevaluatethecardiovascular
risk in ESRD patients [9, 10] as well as in the general popu-
lation [11–14]. Simultaneous assessments of several agents
enable better cardiovascular risk estimation because none of
them is sufficient as a single risk indicator.
The aim of the study was to identify the “inflamed” (vul-
nerable) atherosclerotic plaques within common carotid arter-
ies (CCA) using
99mTc-labelled IL-2 scintigraphy in a selected
group of ESRD patients who are at high cardiovascular risk.
Materials and methods
Atotalof28patients(10women,18men,aged55.2±9.6years)
were included in the study. All patients were treated with
dialysis (17 on peritoneal dialysis, 11 on haemodialysis) due
to ESRD for a median period of 38.4 months (range 4–
133 months). Fifteen patients had diagnosed angina pectoris
in a stable state (including three patients with a history of
myocardial infarction). Information about other “classic”
cardiovascular risk factors (age, sex, diabetes mellitus, hyper-
tension, hypercholesterolaemia, hyperhomocysteinaemia,
smoking) was obtained based on patient histories. The body
mass index (BMI) was calculated on the day of scintigraphy.
Additionally, information about receiving drugs including sta-
tins, angiotensin-converting enzyme inhibitors (ACEI) and an-
giotensin II receptor antagonists was collected.
The main inclusion criterion was as t a b l ec l i n i c a ls t a t u so v e r
a period of at least 2 months prior to assessment (i.e. displaying
no symptoms of acute coronary event, neoplasm, infectious or
non-infectious inflammatory disease, including dialysis-related
peritonitis or vascular access infection). None of the patients
suffered from a systemic inflammatory disease or received
steroids, non-steroidal anti-inflammatory drugs, antibiotics or
immunosuppressive treatment.
In addition to scintigraphy, an ultrasound examination of
the carotid arteries was performed in order to assess the
674 Eur J Nucl Med Mol Imaging (2012) 39:673–682amount and localization of atherosclerotic plaques and to
measure CCA intima-media thickness (IMT).
Furthermore,serumorplasmalevelsofselected“traditional”
and novel markers of inflammation and atherosclerosis were
measured:
1. Markers of inflammation:
￿ C-reactive protein (CRP) (immunonephelometric
method, Nhighsensitivity CRP, DadeBehringGmbH,
Marburg, Germany)
￿ Fibrinogen (immunonephelometric method, Multi-
fibren U reagent, Dade Behring GmbH, Marburg,
Germany)
￿ Interleukin-6 (IL-6) [enzyme-linked immunosorbent as-
say (ELISA); Quantikine HS, human IL-6, R&D Sys-
tems, Minneapolis, MN, USA]
￿ Interleukin-18 (IL-18) (ELISA; Medical & Biologi-
cal Laboratories Co., Naka-Ku Nagoya, Japan)
￿ Plasma soluble IL-2 receptor (sIL-2R) (ELISA; Quanti-
kine,humanIL-2sRalpha,R&DSystems,Minneapolis,
MN, USA)
￿ Human amyloid A (SAA) (immunonephelometric
method, SAA, Dade Behring GmbH, Marburg,
Germany)
￿ Homocysteine (Hcy) [enzyme immunosorbent assay
(EIA), homocysteine test, Bio-Rad Laboratories, Her-
cules, CA, USA]
￿ Soluble intercellular adhesion molecule (sICAM)
(EIA; human sICAM-1, R&D Systems, Minneapolis,
MN, USA)
￿ Antibodies against heat shock proteins 60 (aHSP60)
(ELISA; Anti-Human Hsp60 (total) ELISA Kit, Assay
Designs Inc., Ann Arbor, MI, USA)
￿ Soluble CD40 ligand (sCD40L) (ELISA; Human
sCD40L ELISA, Diaclone SAS, Besançon, France)
￿ Asymmetric dimethylarginine (ADMA) (ELISA;
ADMA direct ELISA Kit, Immundiagnostik AG,
Bensheim, Germany)
2. Calcium-phosphate balance parameters:
￿ Total calcium (Ca) and ionized calcium (Hitachi 917,
Roche Diagnostics, Division of Hoffmann La Roche,
Basel, Switzerland)
￿ Phosphate (P) (Hitachi 917, Roche Diagnostics, Divi-
sion of Hoffmann-La Roche, Basel, Switzerland)
￿ Calcium-phosphateindexwascalculatedbasedonresults
of calcium and phosphate serum concentration (Ca × P)
￿ Intact parathormone (iPTH) (chemiluminescence
method; Immulite 2000, Diagnostic Products Corpo-
ration, Los Angeles, CA, USA)
3. Detailed lipid profile and anti-atherogenic factors:
￿ Total cholesterol (total-C) (Hitachi 917, Roche Diag-
nostics, Division of Hoffmann-La Roche, Basel,
Switzerland)
￿ Low-density lipoprotein (LDL) cholesterol (LDL-C)
(Hitachi 917, Roche Diagnostics, Division of
Hoffmann-La Roche, Basel, Switzerland)
￿ High-density lipoprotein (HDL) cholesterol (HDL-C)
(Hitachi 917, Roche Diagnostics, Division of
Hoffmann-La Roche, Basel, Switzerland)
￿ Triglyceride (TG) (Hitachi 917, Roche Diagnostics,
Division of Hoffmann-La Roche, Basel, Switzerland)
￿ Apolipoprotein A-I (immunonephelometric method,
N Antisera to Apolipoprotein A-I and Apolipoprotein
B, Dade Behring GmbH, Marburg, Germany)
￿ Apolipoprotein B (immunonephelometric method, N
Antisera to Apolipoprotein A-I and Apolipoprotein
B, Dade Behring GmbH, Marburg, Germany)
￿ Adiponectin (ELISA; human adiponectin, R&D Sys-
tems, Minneapolis, MN, USA)
4. Markers of oxidative stress:
￿ Oxidized LDL (oxLDL) (ELISA; oxLDL ELISA Kit,
Immundiagnostik AG, Bensheim, Germany)
￿ Antibodies against oxidized LDL (anti-oxLDL)
(ELISA; anti-oxLDL IgG OLAB IgG, Biomedica
Gruppe, GmbH & Co KG, Vienna, Austria)
All of the above analyses were performed in duplicate.
Intra-assay variability of measurements was below 3%.
Ten healthy (without any signs of cardiovascular disease)
age- and sex-matched volunteers from among our clinic staff
served as a control group for biochemical analysis (for certain
ethical reasons we found it inappropriate to perform scintigra-
phy in control subjects).
Method of IL-2 labelling with
99mTc
Themethodfor
99mTcradiolabellingofrecombinanthumanIL-
2 (rhIL-2) (Proleukin, Chiron Corp, Emeryville, CA, USA) via
hydrazinonicotinamide (HYNIC) leading to the development
of a dry kit has been previously described in detail [15]. In that
paper we provided the details on tracer optimization, including
the HYNIC to IL-2 molar ratio, the influence of HYNIC-IL-2
conjugate mass on specific activity of obtained
99mTc-HYNIC-
IL-2andeffectofco-ligandsonstabilityof
99mTc-HYNIC-IL-2
both in vitro and in vivo. The biological activity of
99mTc-
HYNIC-IL-2 in the presence of tricine and nicotinic acid (NA)
as co-ligands for
99mTc has been documented in a lymphocyte
proliferation assay. These studies resulted in the kit formulation
rendering the sterile and ready-to-use
99mTc-HYNIC-IL-2(tri-
cine-NA)-rhIL-2 stable within 1 h after completion of the
labelling procedure. Briefly, the conjugates of HYNIC-rhIL-2
were prepared using 2 molar excess of HYNIC-HCl and puri-
fied on a Sephadex G-25 column (PD-10, GE) using 0.05 M
phosphate buffer (pH 7.2) and 0.05% sodium dodecyl sulphate
(SDS) in order to prevent protein aggregation. Dry kits con-
taining 30 μg HYNIC-rhIL-2 conjugate, glucose, phosphate
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in vial I, and tricine and stannous chloride in vial II, were
prepared. For labelling around 1.0 ml of radioactive
99mTc in
the form of sodium pertechnetate 800–1,000 MBq obtained
from the
99Mo/
99mTc radionuclide generator (POLATOM,
Poland) was added to vial II. After incubation at room temper-
ature for 20 min, 0.5 ml of the
99mTc-tricine complex solution
was transferred to vial I containing HYNIC-rhIL-2 conjugate,
followed by incubation at 75°C for 30 min. After purification
on a PD-10 column around 99% pure monomer of
99mTc-
HYNIC-(NA,tricine)-rhIL-2 was obtained with specific activ-
ity greater than 4 GBq/mg of rhIL-2 (62.5GBq/μmol). Aseptic
conditions were maintained during tracer preparation and the
finalproductwascheckedfor sterilityandbacterialendotoxins.
CCA plaque scintigraphy
The scintigraphic examinations were performed using a dual-
head, large field of view e.cam gamma camera (Siemens)
equipped with parallel, low-energy high-resolution (LEHR)
collimators connected to the syngo MI molecular imaging
system workstation.
Single photon emission computed tomography (SPECT)
of the neck was performed 1 h after injection of the tracer.
Every time 128 frames (acquisition time 45 ) were per-
formed on a 64×64 matrix. The target to non-target (T/nT)
ratioforfocal
99mTc-HYNIC-IL-2uptakewascalculatedwith-
in the largest atherosclerotic plaque previously identified by
the CCA ultrasound.
SPECT images were reconstructed using the filtered back-
projection (FBP) method of reconstruction using a Hanning
filterand anattenuation coefficient of0.125 cm
−1.Eighttoten
transaxial sections, each 2 cm thick, were reconstructed from
the origin of the common carotid upwards.
99mTc-HYNIC-IL-
2 uptake as a region of interest (ROI; target, T) was calculated
on SPECT images at the level of the carotid bifurcation in the
place depicted by ultrasonography. The background (nT)
of
99mTc-HYNIC-IL-2 uptake was counted in the region
drawn laterally to the ROI adjacent to the CCA.
CCA ultrasound and IMT measurement
TheCCAIMTwasassessedinB-modepresentationusingGE
Vivid 7 equipment with 5/7 MHz linear transducer (GE
Healthcare, Chalfont St Giles, UK).
An atherosclerotic plaque was defined as an echostruc-
ture with a thickness greater than at least 50% compared to
neighbouring sites with protrusion into the vascular lumen.
Additionally, IMT was measured as an indicator of athero-
sclerosis advancement on the far wall of the CCA 2–4c m
proximally from its bifurcation. IMT had been assessed
bilaterally, but for the purpose of this analysis the result
from the side that displayed the plaque(-s) (or the larger
plaque) was used. The CCA ultrasound was performed on the
day of the scintigraphyexamination about 1 h beforeinjection
of the tracer.
Laboratory assessment
Blood for the analyses was drawn on the day of scintigraphy
prior to the procedure. Fasting blood samples were taken for
analyses of serum concentrations of acute phase reactants,
cytokines, adhesion molecules, markers of oxidative stress,
calcium-phosphate balance parameters and the extended lipid
profile. The blood was centrifuged at a temperature of22°C at
a speed of 3,000 g for 15–30 min and stored at a temperature
of −80° until assayed.
The study protocol was reviewed and accepted by the
independent Ethics Committee of our University. All patients
gave signed informed consent prior to participation in the
study.
Statistical analysis
Differences between the studied and control group (biochemi-
cal tests) were analysed using the χ
2 test and the Fisher exact
test (if small numbers occurred) for categorical variables. The
Mann-Whitney tests were applied for continuous variables.
The Mann-Whitney test was also used to discover factors
associated with the scintigraphy result in the studied group.
When categorized independent variables had more than two
values, the Kruskal-Wallis tests were applied.
The odds ratios of T/nT higher than median (2.2) were
calculated using logistic regression. In tested models, inde-
pendent variables were used as continuous as well as cate-
gorized for terciles. The statistical significance was defined
as p <0.05. All calculations were made using the Stata 8.0
statistical package.
Results
Increased
99mTc-HYNIC-IL-2 uptake was detected in 38 of
41 atherosclerotic plaques (91%) previously visualized by
neck ultrasound. The median T/nT ratio of focal
99mTc-
HYNIC-IL-2 uptake in the region of atherosclerotic plaques
equalled 2.35 (range 1.23–3.63; average 2.35±0.70). The
mean IMT value for the CCA with plaque assessed with
scintigraphy averaged 0.79±0.18 mm (median 0.8; range
0.5–1.275). No statistically significant association was
found between
99mTc-HYNIC-IL-2 T/nT ratio and the mean
value of IMT. However, the difference in T/nT ratio between
atherosclerotic plaques with or without calcification on ul-
trasound was close to statistical significance (2.35±0.68 vs
1.924±0.55, p00.088) (Fig. 1.)
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teins as well as calcium-phosphate parameters were signifi-
cantly higher in the group of patients with ESRD as compared
tothecontrolgroup.The valuesofthelipidprofilecomponent,
however, were not statistically significantly different between
the ESRD patients and the control group (all data presented in
Table 1).
A statistically significant inverse relationship was found
between scintigraphy results (T/nT ratio) and haemoglobin
concentration (R0−0.21, p00.02) (Fig. 2a). Furthermore,
the following parameters correlated significantly with T/nT
ratio: apoB (R031, p00.008), apoB/apoA-I ratio (R00.29,
p00.012) (Fig. 2b), homocysteine (R00.22, p00.037)
(Fig. 2c) and triglycerides (R00.26, p00.021) (Fig. 2d).
Moreover, ADMA concentration, which is considered one
of the strongest risk factors for cardiovascular disease, was
found to be significantly higher in the group of patients in
the third tercile (patients with the highest values) of IL-2
uptake in scintigraphy (Fig. 3).
The multivariate analysisrevealed thatpatients witha better
profile of nutritional parameters (haemoglobin, albumin, adi-
ponectin—all values above median) were characterized with
lower T/nT ratio as compared with patients with a worse
nutritional profile (haemoglobin, albumin, adiponectin—all
values bellow median) (2.16±0.68 vs 3.2±0.5, p00.025)
(Fig. 4a). Similarly, lower values of T/nT ratio were found in
groups of patients characterized by all apoB, sCD40L and
ADMA concentrations below median compared to concentra-
tions above median (2.16±0.68 vs 3.18±0.52, p00.031)
(Fig. 4b).
No correlations were found between scintigraphy results
and cardiovascular events in anamnesis (2.40±0.29 vs 2.23±
0.75,p0NS),classiccardiovascularriskfactors,statinorother
drug treatment. Only three patients declared active smoking;
however, their mean T/nTwas 2.60±1.01 whereas in the non-
smoking group it equalled 2.20±0.67, p0NS.
Examples of scintigraphy results obtained in a 54-year-old
man on peritoneal dialysis with bilateral calcified carotid pla-
quesanda48-year-oldmanonperitonealdialysiswithbilateral
non-calcified carotid plaques are presented in Fig. 5a, b.
Discussion
Searching for methods of short- and long-term cardiovascular
risk assessment is essential and involves many visualization
techniques. Among them, various nuclear medicine techni-
ques offer valuable and specific opportunities due to the wide
range of available methods and tracers.
Currently in humans the easiest and most widely available
nuclearmedicinemethodsinassessingatheroscleroticplaques
are visualizations of the peripheral arteries using SPECT or
planar scintigraphy. Several attempts at atherosclerotic plaque
imaging were unsuccessful since most of the tracers used did
not confirm their clinical utility due to their toxicity [16], long
time of tracer uptake [17], long clearance time [18], low
values of achieved T/nT ratio [19, 20]o ri n t e r a c t i o n sw i t h
drugs used in the treatment of cardiovascular disease [21, 22].
However,someofthemwiththeuseofAnnexinVasamarker
of apoptosis, monocyte chemoattractant protein-1 (MCP-1) as
a marker of macrophage infiltration [23],
111In-Z2D3 F(ab’)2
against proliferating smooth muscles [24]o rI L - 2[ 6, 7]w e r e
promising. Among PET tracers the most advanced studies
used
18F-fluorodeoxyglucose (FDG) and they confirmed in-
creased uptake of that tracer in atherosclerotic plaques [25]
while the arteries without atherosclerotic plaques did not take
up
18F-FDG [26].
Fig. 1 Mean values of T/nT
ratio of
99mTc-HYNIC-IL-2
uptake in atherosclerotic
plaques without and with
calcifications (1.924±0.55 vs
2.35±0.68, p00.088)
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sclerotic visualization have been performed, but neither of
them has clearly answered the question about the relation-
ship between scintigraphic result and chronic inflammation,
considered as a one of the most important cardiovascular
risk factors.
Annovazzi et al. were the first investigators to em-
ploy
99mTc-IL-2 to visualize CCA plaques [6]. They demon-
strated the correlation between three cytological parameters:
the number of IL-2R-positive cells on histopathology, the
absolute number of IL-2R-positive cells as well as the percent-
age of IL-2R-positive cells on flow cytometry and
99mTc-
HYNIC-IL-2 uptake onSPECT. They did not reveal, however,
anyassociationbetweenscintigraphyresultsandplaqueechos-
tructure or surface on ultrasound.
To the bestof our knowledge,wewerethe first topublish a
pilot study with CCA plaque visualization using
123I-IL-2 in
ESRD patients with high cardiovascular risk [7]. The main
findings in that study confirmed the potential usefulness of
thistracerandapplied examinationtechniquesinvisualization
of the inflamed atherosclerotic lesions (100% sensitivity of
scintigraphy in CCA plaque imaging). In that study we also
found a correlation between the quantitative results of scintig-
raphy, the results of IMT measurement and the subsequent
risk of cardiovascular event over the next 3 years offollow-up
(datanotpublishedyet).Theseencouragingresultsinclinedus
towards testing this approach with a better (safer and cheaper)
tracer in a larger group of ESRD patients with slightly lower
cardiovascular risk, thus in patients who could take greater
advantage of cardiovascular risk assessment. In the current
Table 1 The values of measured biochemical parameters in patients with ESRD and in the control group
Parameter Unit ESRD patients Control group Reference range p
Median (range) Median (range)
Haemoglobin g/dl 12.05 (8.4–16.1) 14.30 (12.80–16.00) 11–17 <0.01
White blood count 10
3/μl 5.93 (3.83–14.04) 6.24 (4.15–7.71) 4–10 NS
Albumin g/l 41 (33–56) 45 (45–50) 35.0–50.0 <0.01
Creatinine μmol/l 745.2 (270.3–1134.6) 60.15 (42.80–99.6) 45.0–97.0 <0.01
Urea nitrogen mmol/l 18.50 (12.50–34.80) 4.85 (3.4–6.9) 1.7–8.3 <0.01
Phosphate 1.69 (1.07–2.78) 1.11 (0.77–1.41) 0.87–1.45 <0.01
Total calcium 2.20 (1.80–2.56) 2.36 (2.28–2.32) 2.02–2.61 0.02
Fibrinogen g/l 6.36 (2.50–8.70) 2.76 (2.1 3–3.81) 1.8–3.5 <0.01
C-reactive protein (CRP) mg/l 3.87 (0.26–30.30) 0.98 (0.21–5.1) 0 – 3 0.02
Interleukin-6 (IL-6) pg/ml 2.645 (0.67–19.81) 0.52 (0.27–1.85) 0.447–9.96 <0.01
Soluble IL-2 receptor (sIL-2R) 2,987.5 (1,535–5,739) 893 (699–1323) 458–1997 0.01
Soluble intercellular adhesion molecule-1
(sICAM-1)
ng/ml 304 (210–484) 229.07 (194.35–283.63) 115–306 0.01
Amyloid A (SAA) mg/l 5.7 (1.7–145) 2.3 (0.90–9.7) 5.0–6.4 0.01
Interleukin-18 (IL-18) pg/ml 522.7 (318.4–1437.2) 286.35 (167.5–449.5) 37–215 <0.01
Antibodies to human heat shock protein
60 (aHSP60)
ng/ml 29.21 (8.54–267.32) 23 (16.66–46.50) No data NS
Soluble CD40 ligand (sCD40L) 9.39 (2.92–17.74) 14.49 (7.62–22.11) 1.13–3.13 <0.01
Asymmetric dimethylarginine (ADMA) μmol/l 0.923 (0.267–1.476) 0.579 (0.348–0.968) 0.26–0.64 0.047
Homocysteine 24.8 (8.5–67.2) 10.95 (5.3–17) 3.6–15.0 <0.01
Anti-oxidized LDL 163.25 (65.26–1200) 158.75 (37–1200) No data NS
HDL cholesterol mmol/l 1.24 (0.86–2.35) 1.30 (1.03–2.04) 0.9–3.00 NS
LDL cholesterol 2.6 (1.49–5.42) 3.17 (2.4–6.3) 0.2–3.40 NS
Triglycerides 1.805 (0.9–3.35) 1.39 (0.94–4.83) 0.2–2.30 <0.01
Adiponectin ng/ml 16,846.5 (3,437–43,497) 5,867 (4,080–13,346) 865–21424 <0.01
Apolipoprotein A-I (apoA-I) g/l 1.55 (1.03–2.08) 1.66 (1.37–2.05) W 1.25–2.15 NS
M 1.10–2.05
Apolipoprotein B (apoB) 0.95 (0.56–1.58) 0.96 (0.68–1.72) W 0.55–1.25 NS
M 0.55–1.40
Apolipoprotein B/A-I (apoB/A-I) – 0.59 (0.32–1.27) 0.61 (0.34–0.98) W 0.3–0.9 NS
M 0.55–1.0
Oxidized LDL ng/ml 49.52 (4.13–2340.64) 41.41 (9.88–259.54) 18–2261 NS
Body mass index kg/m
2 25.40 (19.43–34.60) 25.01 (20.82–36.57) 18.5–24.99 NS
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cardiovascular events, classic cardiovascular risk factors and
IL-2 scintigraphy results. Indeed, the lack of correlation prob-
ably resulted from the small number of cardiovascular events
during the observation time, lower patient inflammatory state
in comparison with the
123I study and the relatively short time
of observation (mean 14 months). The lack of a statistically
important impact ofclassic cardiovascular risk factors on IL-2
scintigraphyinthecurrentstudyinthefirstplaceresultedfrom
a relatively small effect of the single factor in cardiovascular
risk and the small groups for statistically important results in
multifactor analysis.
In our present study, in addition to plaque localization
and IMT measurements, we also assessed the presence of
calcifications within the plaque. Surprisingly, we found that
plaques with calcifications were characterized by a higher
Fig. 2 The correlation between
serum concentrations of
haemoglobin (a),
apolipoprotein B/A-I ratio (b),
homocysteine value (c),
triglycerides (d) and T/nT
ratio of
99mTc-HYNIC-IL-2
uptake within atherosclerotic
plaque in ESRD patients
Fig. 3 The differences
of T/nT ratio of
focal
99mTc-HYNIC-IL-2
uptake depending on
ADMA value (terciles) in
CCA walls in ESRD
patients
Eur J Nucl Med Mol Imaging (2012) 39:673–682 679value of T/nT as compared to those without calcification
(2.35±0.68 vs 1.92±0.55, p00.088). This observation may
on the one hand be considered unusual, because many
previous studies have shown that calcified plaques are
“older”, usually with a lower degree of inflammation and
thus more stable. On the other hand, it has been demonstrat-
ed repeatedly that plaque calcification is an active process
with engagement of activated inflammatory cells and proin-
flammatory cytokines [27, 28].
The choice of the best biochemical test for cardiovascular
risk assessment in everyday practice is difficult due to the
overlapping of different diseases in the group of patients with
highcardiovascularrisk(and especially withchronic uraemia).
However, some cytokines (e.g. IL-6, IL-18), acute phase
proteins (e.g. CRP, fibrinogen) or components of the lipid
profile (triglycerides, LDL-C, apoA-I, apoB) seem to be rea-
sonabletoolsforassessmentofthedegreeofinflammationand
concomitant cardiovascular risk.
In the
123I-IL-2 study quoted above we failed to find any
association between scintigraphy results and biochemical
variables, probably because the number of participants was
too small ordue todifferentradiopharmaceutical properties of
the isotopes.
In the present research, the analysis of the relationship
between
99mTc-HYNIC-IL-2 scintigraphy and the results of
the biochemical tests revealed the associations between T/nT
and concentrations of haemoglobin, serum homocysteine,
ADMA, triglycerides, apoB and apoB/apoA-I ratio. These
Fig. 4 a Mean values of T/nT
ratio of
99mTc-HYNIC-IL-2
uptake in patients with better (1)
parameters of nutritional status
(haemoglobin, albumin,
adiponectin) in comparison with
patients with worse (2)
nutritional parameters
(3.20±0.5 vs 2.16±0.68,
p00.025). b Mean values
of T/nT ratio of
99mTc-HYNIC-
IL-2 uptake in patients with
values of apoB, sCD40L and
ADMA below (1) and above (2)
median (2.16±0.68 vs 3.18±
0.52, p00.031)
Fig. 5 The scintigraphy results in a 54-year-old man on peritoneal dialysis with bilateral calcified carotid plaques (a) and a 48-year-old man on
peritoneal dialysis with bilateral non-calcified carotid plaques (b)
680 Eur J Nucl Med Mol Imaging (2012) 39:673–682correlations may indirectly confirm the link between systemic
inflammation (and possibly inflammation activity within an
atherosclerotic plaque) and scintigraphy results. Furthermore,
in ESRD patients the high inflammatory state and signs of
poor nutritional status correlate with higher cardiovascular
risk [8]. The multifactor analyses of laboratory data show
positive correlation between IL-2 uptake and low values
for parameters of nutritional status (haemoglobin, albumin,
adiponectin) as well as negative factors (ADMA, apoB,
sCD40L). Those positive associations achieved in our study
between atherosclerosis and inflammation indicate IL-2 scin-
tigraphy as a potentially valuable method of assessing athero-
sclerotic plaque inflammatory state.
Conclusion
Scintigraphy with
99mTc-HYNIC-IL-2 can be considered a
useful tool for visualizing the inflamed atherosclerotic (vulner-
able) plaque within CCA in ESRD patients. The quantitative
results of the carotid artery
99mTc-HYNIC-IL-2 scintigraphy
correlated with serum concentration of certain biochemical
markers of cardiovascular risk.
PerformingscintigraphywithradiolabelledIL-2inaddition
tocurrently available methods would seemtobea steptoward
a better assessment of cardiovascular risk by recognizing
vulnerable patients through identification of the inflammatory
process within an atherosclerotic plaque. This may enable
earlier, more aggressive treatment, which may lead to the
stabilization of potentially vulnerable plaques.
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